1. Home
  2. QDEL vs MNKD Comparison

QDEL vs MNKD Comparison

Compare QDEL & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo QuidelOrtho Corporation

QDEL

QuidelOrtho Corporation

HOLD

Current Price

$12.25

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Logo MannKind Corporation

MNKD

MannKind Corporation

HOLD

Current Price

$2.81

Market Cap

877.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
QDEL
MNKD
Founded
1979
1991
Country
United States
United States
Employees
N/A
592
Industry
Medical Specialities
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
877.0M
IPO Year
2022
2004

Fundamental Metrics

Financial Performance
Metric
QDEL
MNKD
Price
$12.25
$2.81
Analyst Decision
Hold
Buy
Analyst Count
4
8
Target Price
$28.25
$8.69
AVG Volume (30 Days)
2.6M
3.3M
Earning Date
05-05-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
45.35
N/A
EPS
N/A
0.02
Revenue
$2,730,200,000.00
$348,966,000.00
Revenue This Year
$3.51
$35.81
Revenue Next Year
$3.86
$11.89
P/E Ratio
N/A
$140.00
Revenue Growth
N/A
22.23
52 Week Low
$10.86
$2.23
52 Week High
$37.24
$6.51

Technical Indicators

Market Signals
Indicator
QDEL
MNKD
Relative Strength Index (RSI) 40.56 50.40
Support Level $10.86 $2.56
Resistance Level $17.78 $2.98
Average True Range (ATR) 0.98 0.13
MACD 0.17 0.04
Stochastic Oscillator 21.15 53.85

Price Performance

Historical Comparison
QDEL
MNKD

About QDEL QuidelOrtho Corporation

QuidelOrtho Corp is engaged in the development, manufacturing, and marketing of rapid diagnostic testing solutions. The company is engaged in immunoassay and molecular testing, clinical chemistry, and transfusion medicine, which helps clinicians and patients to make decisions across the globe. Geographically, the company has its presence in North America, EMEA, China, and Other countries. It generates the majority of its revenue from North America.

About MNKD MannKind Corporation

MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.

Share on Social Networks: